This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.theguardian.com/business/2020/jul/27/astrazeneca-deal-cancer-treatment-daiichi-sankyo

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
AstraZeneca signs deal worth up to £4.7bn for cancer treatment AstraZeneca agrees to pay up to £4.7bn for cancer drug
(about 7 hours later)
Pharmaceuticals company buys global rights to new technology from Japan’s Daiichi Sankyo UK-based company hopes deal with Daiichi Sankyo will lead to new breast and lung cancer treatment
Drugmaker AstraZeneca could pay up to $6bn (£4.7bn) for the global rights to a new Japanese cancer treatment. AstraZeneca has agreed a deal worth as much as £4.7bn with a Japanese drug company to develop and market a potential new cancer treatment.
The Anglo-Swedish pharmaceutical company said it would pay $1bn (£800m) up front to its partner Daiichi Sankyo. The British–Swedish pharmaceutical company said it would pay $1bn (£800m) upfront to its partner, Daiichi Sankyo, in what is the latest of a series of bets by the pharma company on oncology treatments.
It has also promised to pay up to $1bn if the treatment gets approval from regulators and up to $4bn (£3.1bn) more if it sells as hoped. AstraZeneca has also promised to pay up to $1bn if the treatment, which it hopes to use for lung and breast cancers, gets approval from regulators and up to $4bn (£3.1bn) more if it sells as hoped.
The treatment, DS-1062, targets the Trop2 protein, which is overproduced by most breast and lung cancers. Honing in on the cells that produce too much of the protein allows the treatment to deliver selective chemotherapy to certain areas, rather than subjecting the whole body to the treatment. The drugmaker has received increased interest from investors during 2020 thanks to successful early trials of a potential coronavirus vaccine in partnership with the University of Oxford. The potential vaccine is undergoing mass trials in Brazil and South Africa to see if it prevents infection by Sars-CoV-2, the virus which has caused the Covid-19 pandemic.
However, AstraZeneca’s rise to the top of the UK’s FTSE 100 index by market value has been founded on investments in cancer drugs that can potentially bring in billions of pounds of revenues. Its bestselling cancer drug, Tagrisso, brought in $3.2bn in sales last year. Two others, Imfinzi and Lynparza, made more than $1bn apiece.
The latest potential cancer treatment, DS-1062, targets the Trop2 protein, which is overproduced by most breast and lung cancers. Homing in on the cells that produce too much of the protein allows the treatment to deliver selective chemotherapy to certain areas, rather than subjecting the whole body to the treatment.
The medicine has not yet been approved for use in any country, and its safety and efficacy have not been established.The medicine has not yet been approved for use in any country, and its safety and efficacy have not been established.
“We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express Trop2,” said the AstraZeneca chief executive, Pascal Soriot. “We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express Trop2,” said AstraZeneca’s chief executive, Pascal Soriot.
The deal will give AstraZeneca a slice of the global sales of the treatment, as the two companies have agreed to partner up to develop and then commercialise DS-1062. The deal will give AstraZeneca a slice of the global sales of the treatment, as the two companies have agreed to partner up to develop and then commercialise DS-1062. However, Daiichi Sankyo will keep the exclusive rights to the Japanese market.
However, Daiichi Sankyo will keep the exclusive rights to the Japanese market. In March last year the two drug companies started a similar partnership to develop and commercialise the breast cancer treatment Enhertu.
It is not the first time the two drug giants have collaborated.In March last year, they started a similar partnership to develop and commercialise breast cancer treatment Enhertu. Soriot said: “We now have six potential blockbusters in oncology with more to come in our early and late pipelines.”
“We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of Enhertu to further expand our pipeline and leadership in oncology,” Soriot said. Daiichi Sankyo’s chief executive, Sunao Manabe, said the new treatment could become “best in class” for targeting and treating multiple tumours, including breast and lung cancers.
He added: “We now have six potential blockbusters in oncology with more to come in our early and late pipelines.”
The Daiichi Sankyo chief executive, Sunao Manabe, said the new treatment could become “best in class” for targeting and treating multiple tumours, including breast and lung cancers.
“This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible,” he said.“This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible,” he said.